MK-571 sodium

LTD4:0.22 nM (Ki, In guinea pig lung)|LTD4:2.1 nM (Ki, In human lung)

在类肺部,MK-571可抑制[3H]LTD4的结合（Ki：2.1±1.8 nM,n=29）,而在豚鼠肺中的Ki值为0.22±0.15 nM (n=35)。但其对[3H]LTC4的结合活性较低或没有活性（IC50：32 μM,n=1,人；23±11 μM,n=16,豚鼠）。

MK-571在健康年轻人体内耐受性良好.口服可被迅速吸收,血药浓度在给药后1.1-1.5 h后达峰.

H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:25.78 mg/mL (48 mM);Ethanol:Insoluble

Cells were seeded onto 96 well plates at a concentration of 1×103 cells per well and incubated for 72 h at 37?C and 5% CO2 to allow MRP1 messenger RNA suppression to occur. Cells were then treated with either control media or one of three chemotherapy drugs temozolomide (150 µM), vincristine (100 nM), or etoposide (2 µM). Cells were then returned to the incubator for a further 72 h; after which time, Metylthiazol Tetrazolium (MTT) powder in PBS (50µl of 5 mg/ml) was added to each well. Cells were then incubated for a further 4 h after which all solution was removed and dimethyl sulfoxide (DMSO) was added. After 10 min incubation time at 37?C, absorbance was recorded at 570 nm wavelength and data was recorded and analyzed. Small molecule inhibitors MK571 (25 µM) and Reversan (15µM) were added 7 h prior to carrying out further drug treatment (temozolomide, vincristine or etoposide) or assay assessment (media change for proliferation and 2D-migration assays) (Only for Reference)